91 related articles for article (PubMed ID: 22523841)
21. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
[TBL] [Abstract][Full Text] [Related]
23. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
[TBL] [Abstract][Full Text] [Related]
24. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
25. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
26. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
Morace G; Polonelli L;
Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
[TBL] [Abstract][Full Text] [Related]
28. In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods.
Torres-Rodríguez JM; Alvarado-Ramírez E
J Antimicrob Chemother; 2007 Sep; 60(3):658-61. PubMed ID: 17623690
[TBL] [Abstract][Full Text] [Related]
29. Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole.
Khan ZU; Randhawa HS; Chehadeh W; Chowdhary A; Kowshik T; Chandy R
Int J Antimicrob Agents; 2009 Jun; 33(6):559-63. PubMed ID: 19195846
[TBL] [Abstract][Full Text] [Related]
30. Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E-test methods.
Sóczó G; Kardos G; McNicholas PM; Falusi E; Gergely L; Majoros L
Mycoses; 2007 May; 50(3):178-82. PubMed ID: 17472612
[TBL] [Abstract][Full Text] [Related]
31. Attempts to Access a Series of Pyrazoles Lead to New Hydrazones with Antifungal Potential against
Negru G; Kamus L; Bîcu E; Shova S; Sendid B; Dubar F; Ghinet A
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641405
[TBL] [Abstract][Full Text] [Related]
32. Heterocycle Thiazole Compounds Exhibit Antifungal Activity through Increase in the Production of Reactive Oxygen Species in the Cryptococcus neoformans-Cryptococcus gattii Species Complex.
Sá NP; Lima CM; Lino CI; Barbeira PJS; Baltazar LM; Santos DA; Oliveira RB; Mylonakis E; Fuchs BB; Johann S
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533240
[TBL] [Abstract][Full Text] [Related]
33. Antifungal activity of eicosanoic acids isolated from the endophytic fungus Mycosphaerella sp. against Cryptococcus neoformans and C. gattii.
Pereira CB; Pereira de Sá N; Borelli BM; Rosa CA; Barbeira PJS; Cota BB; Johann S
Microb Pathog; 2016 Nov; 100():205-212. PubMed ID: 27693577
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
[TBL] [Abstract][Full Text] [Related]
35. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Giannini D; Camiletti V; Fileni B; Giacometti A; Di Francesco LF; Scalise G
J Antimicrob Chemother; 2001 Dec; 48(6):769-73. PubMed ID: 11733459
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles.
Pinto e Silva AT; Costa-de-Oliveira S; Silva-Dias A; Pina-Vaz C; Rodrigues AG
FEMS Yeast Res; 2009 Jun; 9(4):626-33. PubMed ID: 19385998
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2005 Aug; 43(8):3807-10. PubMed ID: 16081915
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel antifungal nonapeptide generated by combinatorial approach.
Kumar M; Chaturvedi AK; Kavishwar A; Shukla PK; Kesarwani AP; Kundu B
Int J Antimicrob Agents; 2005 Apr; 25(4):313-20. PubMed ID: 15784311
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of some hydrazone derivatives as new anticandidal and anticancer agents.
Altıntop MD; Özdemir A; Turan-Zitouni G; Ilgın S; Atlı Ö; İşcan G; Kaplancıklı ZA
Eur J Med Chem; 2012 Dec; 58():299-307. PubMed ID: 23142671
[TBL] [Abstract][Full Text] [Related]
40. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.
Lockhart SR; Iqbal N; Bolden CB; DeBess EE; Marsden-Haug N; Worhle R; Thakur R; Harris JR;
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):144-8. PubMed ID: 22494557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
